Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (Ixekizumab): Effekt hos tidigare användare av Secukinumab i plackpsoriasis

Behanslingssvar på ixekizumab hos patienter som hade ett otillräckligt svar på secukinumab har utvärderats i retrospektiva studier. Lilly har inte genomfört systematiska studier i detta ämne.

Independent Retrospective Reviews of Patients Switched From Secukinumab to Ixekizumab

Table 1 summarizes 5 independent retrospective analyses of the safety and efficacy of ixekizumab in patients previously exposed to secukinumab. These studies were not sponsored by Lilly.

Table 1. Independent Retrospective Reviews of Patients Who Failed Secukinumab Treatment for Psoriasis and Subsequently Received Ixekizumab

Study Type

Inclusion Criteria

Number of Patients

Efficacy Assessment

Safety Assessment

Multicenter retrospective chart review1

- 18 years or older
- moderate-to-severe psoriasis
- treated with ixekizumab therapy following discontinuation of secukinumab

31

22 patients (71.0%) achieved PASI 75 or PGA of 0/1 after 12 weeks of ixekizumab

11 patients (35.5%) experienced ≥1 AE

Single center retrospective analysis2

- moderate-to-severe psoriasis vulgaris (BSA >10 or PASI >10 and DLQI >10 as defined by European consensus and German guidelines)
- previously treated with 3 or more biological therapies
- primary (not achieving ≥ 50 PASI) and/or secondary (losing initial efficacy during treatment) failure to secukinumab
- switched directly from secukinumab to ixekizumab

12

12 patients (100%) achieved PASI 90 and 7 patients (58.3%) achieved PASI 100 after 12 weeks of ixekizumab

2 patients (16.7%) experienced adverse reactions

Multicenter retrospective observational study3

- plaque-type psoriasis
- treated with ixekizumab following discontinuation of secukinumab treatment

69

At week 12
- 56 patients (81.2%) achieved PASI 75
- 50 patients (72.4%) achieved PASI 90, and
- 28 patients (40.5%) achieved PASI 100.

 

Fifty of the 69 patients (72.4%) reached 24 weeks of ixekizumab treatment. At week 24
- 40 patients (80%) achieved PASI 75
- 34 patients (68%) achieved PASI 90, and
- 19 patients (38%) achieved PASI 100

4 patients (5.8%) experienced injection site reactions

No other AE were included in the manuscript

Single center retrospective observational study4

- moderate-to-severe psoriasis
- secukinumab to ixekizumab switch

25

At the end of the surveillance period
- 15 patients (68%) achieved PASI 75
- 9 patients (41%) achieved PASI 90, and
- 5 patients (23%) achieved PASI 100.

Not included

Retrospective study5

- moderate-to-severe psoriasis
- incomplete initial response or loss of efficacy with secukinumab subsequently treated with ixekizumab

14

At week 16, 13 patients (92.9%) had PGA of 0/1

Not included

Abbreviations: AE = adverse event; BSA = body surface area; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index; PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index; PASI 90 = 90% improvement from baseline in Psoriasis Area and Severity Index; PASI 100 = 100% improvement from baseline in Psoriasis Area and Severity Index; PGA = Physician Global Assessment.

Therapeutic Indication

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.6

References

1. Georgakopoulos JR, Phung M, Ighani A, et al. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week multicenter, retrospective study. [published online May 30, 2018]. JEADV. https://dx.doi.org/10.1111/jdv.15100

2. Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat. 2019;30(3):216-220. http://dx.doi.org/10.1080/09546634.2018.1506081

3. Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547-1548. http://dx.doi.org/10.1111/bjd.17580

4. Sherman S, Cohen ES, Amitay-Laish I, et al. IL-17a inhibitor switching - efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol. 2019;99(9):769-773. http://dx.doi.org/10.2340/00015555-3200

5. Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol. 2019;33(9):e338-e341. http://dx.doi.org/10.1111/jdv.15630

6. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

BSA = body surface area

DLQI = Dermatology Life Quality Index

Lilly = Eli Lilly and Company

PASI = Psoriasis Area and Severity Index

PASI75 = 75% improvement from baseline in Psoriasis Area and Severity Index

PASI90 = 90% improvement from baseline in Psoriasis Area and Severity Index

PASI100 = 100% improvement from baseline in Psoriasis Area and Severity Index

PGA = Physician Global Assessment

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M07 10


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss